IMS Anticipates Decline, And Opportunities, For Branded Generics
This article was originally published in PharmAsia News
Executive Summary
IMS Health anticipates government pricing pressure will make it harder for branded generics in emerging markets, but in the right market and with the right approach, large opportunities remain.